ReviewThe Lancet. Oncology2012
Immunotherapies for non-small-cell lung cancer and mesothelioma.
Review in The Lancet. Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.Journal of cancer research and clinical oncology · 2017Trial
- Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer.Immunologic research · 2017Trial
- High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Oncotarget · 2015Trial
- Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Trial
- RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- Prostaglandin D2 axis impairs immunity against melanoma via dendritic cells and γδ T cells in middle-aged mice.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Current status and future perspectives of multi-modal bacteria-based cancer therapies.Clinical and translational medicine · 2025Review
- Hyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma.Biomolecules · 2025Review
- Review
- Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors.Cardio-oncology (London, England) · 2024Article
- Prognostic factors for long-term survival following complete resection by lobectomy in stage I non-small cell lung cancer.Thoracic cancer · 2022Article
- The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?Molecules (Basel, Switzerland) · 2022Review
- Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.Frontiers in oncology · 2022Review
- The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy.PloS one · 2022Article
- MUC20 as a novel prognostic biomarker in ccRCC correlating with tumor immune microenvironment modulation.American journal of cancer research · 2022Article
- GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.Oncoimmunology · 2021Article
- Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors.Frontiers in pharmacology · 2021Article
- Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation.Cancer immunology, immunotherapy : CII · 2020Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Non-small-cell lung cancer and mesothelioma are thoracic malignancies, which in their advanced stages are incurable and have poor prognosis. Advances in our understanding of immune responses to tumours, tumour immunosuppression mechanisms, and tumour-specific shared antigens enabled successful early clinical trials of several specific and non-specific immunotherapies. For non-small-cell lung cancer, phase 3 clinical trial results of Toll-like receptor agonists show little promise. However, ongoing phase 3 trials are assessing melanoma-associated antigen A3 vaccine, liposomal BLP25, belagenpumatucel-L, and talactoferrin. In mesothelioma, immunotherapies being investigated include dendritic cell-based and Listeria-based vaccines, and allogeneic tumour cell and WT1 analogue peptide vaccines. Selection of appropriate patients and disease stages for immunotherapy, measurement of tumour-specific immune responses, and understanding the association between immune and clinical responses are some of the major challenges for the development of immunotherapies for these malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.